TBPH Q2 2022 Earnings — Theravance Biopharma, Inc. Revenue & Financial Results | Market Cap Arena

TBPHTheravance Biopharma, Inc.

$716M

Q2 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$11M-14.4% YoY

Gross Profit

-$4M-35.1% margin

Operating Income

-$23M-209.1% margin

Net Income

-$8M-74.1% margin

EPS (Diluted)

$-0.11

QoQ Revenue Growth

-16.3%

Cash Flow

Operating Cash Flow

-$15M

Free Cash Flow

-$15M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$361M

Total Liabilities

$711M

Stockholders' Equity

-$350M

Cash & Equivalents

$87M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$11M	$13M	-14.4%
Gross Profit	-$4M	-$38M	+89.9%
Operating Income	-$23M	-$64M	+64.0%
Net Income	-$8M	-$52M	+84.4%

Revenue Segments

YUPELRI Monotherapy

$17M61%

Viatris collaboration agreement

$11M39%